Christopher J. Scoggins Form 3 Filing for Abbott Laboratories Stock Options

This Form 3 filing reports the initial beneficial ownership of Abbott Laboratories common shares by Christopher J. Scoggins, Executive Vice President of the company. The filing discloses Scoggins' ownership of 63,621 common shares and eight separate stock option grants with varying expiration dates from 2029 to 2035. The options were granted under the Abbott Laboratories 2017 Incentive Stock Program and are exempt from Section 16 under Rule 16b-3. The options have exercise prices ranging from $75.90 to $135.42 per share and vesting schedules that extend through 2028. The filing includes a power of attorney authorizing company representatives to file SEC documents on Scoggins' behalf. This represents standard disclosure of executive equity compensation and ownership as required for new officers under Section 16 of the Securities Exchange Act.